6 results about "Scleroderma disease" patented technology

Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.

This invention relates to the field of pharmaceutical technology, and particularly to the application of thiostrepton in the preparation of drugs for the prevention and treatment of scleroderma. The application of thiostrepton provides a new treatment approach for a wide range of scleroderma patients, offering clinicians and patients more options. For scleroderma patients intolerant to immunosuppressants, thiostrepton can provide topical, oral, or injectable treatments, avoiding the toxic side effects of immunosuppressants. Thiostrepton can be chemically synthesized, making it less expensive than biological agents. Furthermore, as a drug, it has been approved for use in animals, with fewer and milder side effects.

This invention discloses a method for constructing a PBMC-derived humanized mouse scleroderma model. Human peripheral blood mononuclear cells are transplanted into immunodeficient mice, and a human immune system is reconstructed in the mice. Bleomycin is injected into the local skin of the mice in a round-point manner to induce fibrosis and form a scleroderma model. This application can more comprehensively simulate the complex pathological process of immune abnormalities and tissue fibrosis coexisting in human scleroderma, and provides a more realistic and systematic experimental platform for in-depth exploration of the immune mechanism of this disease.

A kind of nitrogen-containing heterocyclic protein inhibitor compound, its stereoisomer, tautomer or pharmaceutically acceptable salt, also provides preparation of nitrogen-containing heterocyclic compound and its use, the drug prepared using the compound is widely used in the treatment of diseases, wherein the diseases include multiple types of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus, neurodermatitis, dermatitis, psoriasis, psoriatic arthritis, Crohn's disease, Sjogren's syndrome and scleroderma.

One objective is to provide an A2aR antagonist suitable for treating neurological disorders, fibrosis-related diseases (NASH and scleroderma), and cancer. [Solution] Substituted purine compounds of formulas (I) to (III) and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's disease 5, and Parkinson's disease. Pharmaceutical compositions containing such compounds and methods of their use in treating depression are also taught. JPEG2026074001000043.jpg70170